Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH
Shots:
- Hanmi to receive $10M up front- $860M as development- regulatory approval- and commercialization of efinopegdutide along with royalties on sales of the approved product
- Merck to receive an exclusive license to develop- manufacture and commercialize efinopegdutide in the US and globally while Hanmi to retain an option to commercialize the therapy in Korea
- Efinopegdutide is a GLP-1/glucagon receptor dual agonist- activating the both the GLP-1 and glucagon receptors- currently being evaluated in multiple P-I & P-II studies- including for the treatment of severely obese individuals with/without T2D
Ref: Merck & Co. | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com